Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alicia Northall

Postdoctoral Researcher


How can neuroimaging provide biomarkers for neurodegenerative diseases? My research investigates this question in Amyotrophic Lateral Sclerosis (ALS), the most common form of Motor Neuron Disease (MND). ALS is characterised by a rapidly-progressing loss of motor control, typically resulting in death within two years.  

More specifically, I utilise recent advances in neuroimaging methods and analysis that offer unprecedented spatial (e.g., 7T-MRI) and temporal (e.g., MEG) resolution. I use these methods, including multimodal 3T-MRI, to characterise ALS in as much detail as possible. This often includes early stage ALS patients and asymptomatic gene carriers.

My wider interests include the effects of environmental factors, such as nutrition and physical activity, on the risk and onset site of ALS. 

I am part of the Oxford Motor Neuron Disease Centre within the Nuffield Department of Clinical Neurosciences, where I am supervised by Prof. Martin Turner. In addition, I am part of the Oxford-GSK Institute for Molecular and Computational Medicine (IMCM) within the Nuffield Department of Medicine.

Recent publications

More publications